Israel headquartered Oramed’s subsidiary Oravax Medical Inc., and India’s Premas Biotech reported positive preliminary data from a Phase 1 trial in South Africa of an oral Covid-19 vaccine candidate.
Oravax Medical is a clinical-stage vaccine company developing oral vaccines that combine Premas Biotech’s D-Crypt™ Platform with Oramed Pharmaceuticals’ POD™ technology.
Dr Prabuddha Kundu, co-founder and danaging Director, Premas Biotech said, “These results, together with the recent evolution of the Covid strains, further raise our confidence in the success of an oral Covid-19 vaccine and the broad potential of our platform along with Oramed’s POD™ platform to explore oral vaccines for other infectious diseases.”
Nadav Kidron, chairman of Oravax and CEO of Oramed Pharmaceuticals, said, “We’re very encouraged by this initial data, which indicates that our platform can be safely and successfully used to orally deliver protein-based vaccines.”
